[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL248095A0 - Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir - Google Patents

Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir

Info

Publication number
IL248095A0
IL248095A0 IL248095A IL24809516A IL248095A0 IL 248095 A0 IL248095 A0 IL 248095A0 IL 248095 A IL248095 A IL 248095A IL 24809516 A IL24809516 A IL 24809516A IL 248095 A0 IL248095 A0 IL 248095A0
Authority
IL
Israel
Prior art keywords
darunavir
emtricitabine
tenofovir
ritonavir
dosage form
Prior art date
Application number
IL248095A
Other languages
Hebrew (he)
Inventor
Hrakovsky Julia
Haronsky Elina
Nitzan Shahar
Original Assignee
Teva Pharma
Hrakovsky Julia
Haronsky Elina
Nitzan Shahar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Hrakovsky Julia, Haronsky Elina, Nitzan Shahar filed Critical Teva Pharma
Publication of IL248095A0 publication Critical patent/IL248095A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL248095A 2014-04-08 2016-09-27 Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir IL248095A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461976917P 2014-04-08 2014-04-08
US201562119520P 2015-02-23 2015-02-23
PCT/IB2015/052493 WO2015155673A1 (en) 2014-04-08 2015-04-07 Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir

Publications (1)

Publication Number Publication Date
IL248095A0 true IL248095A0 (en) 2016-11-30

Family

ID=53264692

Family Applications (1)

Application Number Title Priority Date Filing Date
IL248095A IL248095A0 (en) 2014-04-08 2016-09-27 Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir

Country Status (6)

Country Link
EP (1) EP3129009A1 (en)
AU (1) AU2015245217A1 (en)
CA (1) CA2942877A1 (en)
IL (1) IL248095A0 (en)
TW (1) TW201622731A (en)
WO (1) WO2015155673A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6433085B2 (en) 2013-04-09 2018-12-05 ボストン バイオメディカル, インコーポレイテッド 2-acetylnaphtho [2,3-b] furan-4,9-dione for use in the treatment of cancer
KR101820084B1 (en) * 2016-03-31 2018-01-18 한미약품 주식회사 Solid formulation for oral administration containing tenofovir disoproxil and a process for the preparation thereof
KR101777564B1 (en) 2016-05-30 2017-09-12 영남대학교 산학협력단 Tablet composition comprising tenofovir disoproxil free base and preparation method thereof
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020512377A (en) * 2017-03-30 2020-04-23 ボストン バイオメディカル, インコーポレイテッド Composition for treating and / or preventing cancer
CN108727401A (en) * 2017-04-20 2018-11-02 盐城迪赛诺制药有限公司 Darunavir novel crystal forms and its preparation method and application
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
CN111407736A (en) * 2020-03-30 2020-07-14 苏州弘森药业股份有限公司 Preparation process of tenofovir disoproxil fumarate tablets

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
KR100296463B1 (en) 1992-08-25 2001-10-24 죤 에이치. 뷰센 Hydroxyethylaminosulfonamide Useful as Retroviral Protease Inhibitor
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
MY121765A (en) 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
AP2089A (en) 2003-01-14 2010-01-11 Gilead Sciences Inc Compositions and methods for combination antiviraltherapy
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
MXPA06014930A (en) * 2004-07-08 2007-02-28 Tibotec Pharm Ltd Combination of anti-hiv reverse transcriptase and protease inhibitors.
TWI471145B (en) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc Unitary pharmaceutical dosage form
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
EP2160394A1 (en) * 2007-05-22 2010-03-10 Ultimorphix Technologies B.v. Tenofovir disoproxil hemi-fumaric acid co-crystal
PA8809601A1 (en) 2007-12-24 2009-07-23 Cipla Ltd ANTI-RETROVIRAL COMBINATION
EP2365798A2 (en) * 2008-11-21 2011-09-21 Ultimorphix Technologies B.v. Wet granulation of tenofovir, emtricitabine and efavirenz
EP2332544A1 (en) 2009-11-20 2011-06-15 Assistance Publique, Hopitaux De Paris New pharmaceutical composition suitable for treating persons affected by human immunodeficiency virus (HIV)
EP2332532A1 (en) * 2009-11-20 2011-06-15 Assistance Publique, Hopitaux De Paris New multi-therapy administration patterns suitable for treating persons affected by human immunodeficiency virus (HIV)
CN103841962B (en) 2011-07-07 2016-08-17 爱尔兰詹森科学公司 Darunavir preparation
WO2013057469A1 (en) 2011-10-20 2013-04-25 Cipla Limited Pharmaceutical antiretroviral compositions
GB201119032D0 (en) * 2011-11-03 2011-12-14 Isis Innovation Multisomes: encapsulated droplet networks
EA026138B1 (en) * 2012-02-03 2017-03-31 Джилид Сайэнс, Инк. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
US20140163096A1 (en) * 2012-12-07 2014-06-12 Pam Golden Methods and compositions for treating hiv-associated diarrhea
IN2013MU01749A (en) 2013-05-15 2015-06-26 Cipla Ltd
MX2016002560A (en) * 2013-08-29 2016-10-26 Teva Pharma Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir.

Also Published As

Publication number Publication date
CA2942877A1 (en) 2015-10-15
EP3129009A1 (en) 2017-02-15
TW201622731A (en) 2016-07-01
AU2015245217A1 (en) 2016-10-13
WO2015155673A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
HK1249103B (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
HK1248547A1 (en) Pharmaceutical formulations comprising tenofovir and emtricitabine
EP3302442A4 (en) Dosage forms and use thereof
IL248095A0 (en) Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
IL252397A0 (en) Pharmaceutical composition, preparation and uses thereof
IL290114A (en) Pharmaceutical composition, preparation and uses thereof
HK1220390A1 (en) Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
PL3229843T3 (en) Pharmaceutical composition, preparation and uses thereof
HK1223630A1 (en) Dosage and administration anti-egfr therapeutics -egfr
HRP20181406T1 (en) Pharmaceutical dosage forms
HRP20182167T1 (en) Benzylhydroxyde derivatives, preparation thereof and therapeutic use thereof
PT3023093T (en) Medicinal preparation based on diosmectite